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Abstract
Background: Salmonella is a major bacterial pathogen transmitted commonly through food. 
Increasing resistance to antimicrobial agents (e.g., ceftriaxone, ciprofloxacin) used to treat serious 
Salmonella infections threatens the utility of these agents. Infection with antimicrobial-resistant 
Salmonella has been associated with increased risk of severe infection, hospitalization, and death. 
We describe changes in antimicrobial resistance among nontyphoidal Salmonella in the United 
States from 1996 through 2009.
Methods: The Centers for Disease Control and Prevention’s National Antimicrobial Resistance 
Monitoring System conducts surveillance of resistance among Salmonella isolated from humans. 
From 1996 through 2009, public health laboratories submitted isolates for antimicrobial 
susceptibility testing. We used interpretive criteria from the Clinical and Laboratory Standards 
Institute and defined isolates with ciprofloxacin resistance or intermediate susceptibility as 
nonsusceptible to ciprofloxacin. Using logistic regression, we modeled annual data to assess 
changes in antimicrobial resistance.
Results: From 1996 through 2009, the percentage of nontyphoidal Salmonella isolates resistant 
to ceftriaxone increased from 0.2% to 3.4% (odds ratio [OR] = 20, 95% confidence interval [CI] 
6.3–64), and the percentage with nonsusceptibility to ciprofloxacin increased from 0.4% to 2.4% 
(OR = 8.3, 95% CI 3.3–21). The percentage of isolates that were multidrug resistant (resistant to ≥ 
3 antimicrobial classes) decreased from 17% to 9.6% (OR = 0.6, 95% CI 0.5–0.7), which was 
driven mainly by a decline among serotype Typhimurium. However, multidrug resistance 
increased from 5.9% in 1996 to a peak of 31% in 2001 among serotype Newport and increased 
from 12% in 1996 to 26% in 2009 (OR = 2.6, 95% CI 1.1–6.2) among serotype Heidelberg.
Conclusions: We describe an increase in resistance to ceftriaxone and nonsusceptibility to 
ciprofloxacin and an overall decline in multidrug resistance. Trends varied by serotype. Because of 
evidence that antimicrobial resistance among Salmonella is predominantly a consequence of 
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antimicrobial use in food animals, efforts are needed to reduce unnecessary use, especially of 
critically important agents.
Introduction
EACH YEAR IN THE UNITED STATES, nontyphoidal Salmonella is estimated to cause 1.2 million 
illnesses, with 23,000 hospitalizations and 450 deaths (Scallan et al., 2011). Five serotypes 
(Enteritidis, Typhimurium, Newport, Javiana, and Heidelberg) typically account for about 
half of laboratory-confirmed illnesses (CDC, 2005–2009). The predominant serotypes 
reflect their different abilities to persist in animals, be transmitted through the food supply, 
and cause human illness (McDermott, 2006; Jones et al., 2008). Infections have been linked 
to a variety of food sources, particularly foods of animal origin (e.g., beef, poultry, eggs, 
dairy products), and fruits and vegetables consumed raw (Braden, 2006; Varma et al., 2006; 
CDC, 2006; Greene et al., 2008; CDC, 2011a).
Most nontyphoidal Salmonella infections result in gastroenteritis and do not require 
treatment with antimicrobial agents. However, these agents are essential for the treatment of 
invasive infections such as bacteremia and meningitis (Pegues and Miller, 2010). 
Fluoroquinolones, such as ciprofloxacin, are frequently prescribed as first-line treatment for 
adults with severe infections (Crump et al., 2003; Pegues and Miller, 2010). Because 
fluoroquinolones are not routinely prescribed for children, ceftriaxone, a third-generation 
ceph-alosporin, is important in the management of invasive infections in children (Gupta et 
al., 2003; Pegues and Miller, 2010). Increasing resistance threatens the utility of these 
agents. Infection with antimicrobial-resistant Salmonella has been associated with increased 
risk of severe infection, hospitalization, and death (Helms et al., 2004; Fisk et al., 2005; 
Varma et al., 2005a; Varma et al., 2005b). Multidrug resistance further complicates 
management by limiting treatment options. We describe an increase in resistance to 
ceftriaxone and nonsusceptibility to ciprofloxacin among nontyphoidal Salmonella. We 
describe an overall decline in multidrug resistance, although we note an increase among 
some serotypes and an increase in specific resistance patterns.
Methods
Participating sites and isolate submission
Public health laboratories routinely receive human Salmonella isolates from clinical 
diagnostic laboratories as part of public health surveillance. Isolates are confirmed as 
Salmonella and serotyped according to the Kaufmann-White Scheme at public health 
laboratories (WHO, 2007). Established in 1996, the National Antimicrobial Resistance 
Monitoring System (NARMS) is a collaboration between the U.S. Food and Drug 
Administration (FDA), U.S. Department of Agriculture, Centers for Disease Control and 
Prevention (CDC), and state and local health departments to monitor resistance among 
Salmonella and other foodborne bacteria (CDC, 2012). In 1996, 13 states participated; by 
2003, NARMS included 50 states (Table 1). Sites submitted every 10th isolate from 1996 
through 2002 and every 20th from 2003 through 2009.
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Antimicrobial susceptibility testing
At CDC, isolates were tested for susceptibility to antimicrobial agents representing eight 
classes (CDC, 2012; CLSI, 2012): aminoglycosides, β-lactam/β-lactamase inhibitor 
combinations, cephems, folate pathway inhibitors, penicillins, phenicols, quinolones, and 
tetracyclines. Minimum inhibitory concentrations (MICs) were determined using a broth 
microdilution method (Sensititre, Trek Diagnostics, Westlake, OH). We used interpretive 
criteria from the Clinical and Laboratory Standards Institute (CLSI) when available (CDC, 
2012; CLSI, 2012). Ceftriaxone resistance was defined as MIC ≥ 4 μg/mL and ceftiofur 
resistance as MIC ≥ 8 μg/mL. In January 2012, CLSI established new ciprofloxacin MIC 
interpretive criteria for extraintestinal Salmonella spp. We used the new criteria for all 
isolates; resistance was defined as MIC ≥ 1 μg/mL, intermediate as MIC = 0.12–0.5 μg/mL, 
and susceptible as MIC ≥ 0.06 μg/mL. We defined isolates that were resistant or 
intermediate as nonsusceptible to ciprofloxacin.
Data analysis
Data were analyzed using SAS version 9.2 (SAS Institute Inc., Cary, NC). Except for 
analyses of nonsusceptibility to ciprofloxacin, isolates were categorized as resistant or not 
resistant (susceptible or intermediate). We included 15 agents in the analysis of 
antimicrobial class resistance. Multidrug resistance (MDR) was defined as resistance to ≥ 3 
classes. Among isolates with MDR, we identified the most common patterns based on seven 
agents: ampicillin (A), chloramphenicol (C), streptomycin (S), sulfonamide (Su), 
tetracycline (T), amoxicillin-clavulanic acid (Au), and ceftriaxone (Cx). These seven agents 
were chosen because MDR patterns (e.g., ACSSuTAuCx, ACSSuT, AAuCx) that include 
many of them have been associated with more severe Salmonella infections (Gupta, et al. 
2003; Fisk et al., 2005), and these agents represent seven of eight classes tested. The patterns 
as assigned were mutually exclusive. A chi-square test was used to test for association with 
resistance/nonsusceptibility patterns. Typhoidal Salmonella isolates (serotypes Typhi, 
Paratyphi A, Paratyphi B [tartrate negative], and Paratyphi C) were excluded in the analysis. 
Hereafter, the term Salmonella refers to nontyphoidal Salmonella. Using logistic regression, 
we modeled annual data from 1996 through 2009 to assess changes in resistance (Kleinbaum 
et al., 2008; CDC, 2012). Only the comparisons between 1996 and 2009 are presented. 
Except where noted, regression models were adjusted for the submitting site using nine 
regions (CDC, 2012): East North Central, East South Central, Mid-Atlantic, Mountain, New 
England, Pacific, South Atlantic, West North Central, and West South Central. For 
calculations of the percentage of a serotype with a given resistance pattern, only serotypes 
with at least three isolates with that pattern were included.
Results
From 1996 through 2009, 24,903 nontyphoidal Salmonella isolates were tested; the most 
common serotypes were Typhimurium (21%), Enteritidis (19%), Newport (9%), and 
Heidelberg (5%). Of 22,532 (90%) patients with reported age, 9% were < 1 year old, 19% 
1–4 years, 9% 5–9 years, 10% 10–19 years, 39% 20–59 years, and 14% ≥ 60 years. Of 
23,199 (93%) patients for whom sex was known, 52% were female. Of 24,248 isolates 
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(97%) with reported specimen source, 88% were from stool, 5% from blood, 4% from urine, 
and 3% from other or undefined sources.
Resistance to ceftriaxone
Among the 24,903 isolates, 730 (2.9%) were resistant to ceftriaxone. They were of 40 
serotypes; most were Newport (45%), Typhimurium (25%), or Heidelberg (11%) (Table 2).
Resistance to ceftriaxone was most common among serotypes Concord (71% of this 
serotype) and Newport (14%). Among Salmonella, ceftriaxone resistance increased from 
0.2% in 1996 to 3.4% in 2009 (odds ratio [OR] = 20, 95% confidence interval [CI] 6.3–64); 
it peaked at 4.4% in 2002 and 2003 (Table 3, Fig. 1). Resistance in Newport isolates was 
found in 0% in 1996 and increased to 7.1% in 2009; it peaked at 25% in 2001. Among 
serotype Typhimurium isolates, resistance increased from 0% in 1996 to 6.5% in 2009 (95% 
CI 6.6–infinity). Among serotype Heidelberg isolates, resistance increased from 2.7% in 
1996 to 8.0% in 2008, then jumped to 21% in 2009 (1996 vs. 2009; OR = 9.4, 95% CI 2.1–
87) (Table 3, Figure 1). Of 24 resistant Typhimurium isolates in 2009, 6 (25%) were from 
California. Of 18 resistant Heidelberg isolates in 2009, 9 (50%) were from California and 3 
(17%) were from Washington.
Ceftiofur resistance also increased and was correlated with ceftriaxone resistance (p < 0.01). 
Among all isolates, 737 (3.0%) were resistant to ceftiofur; 99% of the ceftiofur-resistant 
isolates were resistant to ceftriaxone (Table 2).
Resistance and nonsusceptibility to ciprofloxacin
Among the 24,903 isolates, 40 (0.2%) were resistant to ciprofloxacin. They were of 13 
serotypes; most were Senftenberg (38%), Typhimurium (15%), or Litchfield (10%), and no 
other serotype comprised ≥ 10% of resistant isolates (Table 2). Serotypes with the highest 
proportion of isolates resistant to ciprofloxacin were Senftenberg (13%) and Litchfield 
(2.9%). In addition, 442 (1.8%) isolates had intermediate susceptibility to ciprofloxacin. 
They were of 57 serotypes; most were Enteritidis (42%), Typhimurium (13%), or Virchow 
(8.1%). However, only 4.0% of Enteritidis isolates had intermediate susceptibility to 
ciprofloxacin. Serotypes for which a high proportion of isolates had intermediate 
susceptibility were Corvallis (88%), Virchow (43%), Concord (43%), Choleraesuis (25%), 
and Blockley (20%) (Table 2). Among Salmonella, nonsusceptibility to ciprofloxacin 
increased from 0.4% in 1996 to 2.4% in 2009 (OR = 8.3, 95% CI 3.3–21). Among serotype 
Enteritidis isolates, the percentage increased from 0.9% in 1996 to 3.7% in 2009 (OR = 5.3, 
95% CI 1.5–19); it peaked at 7.0% in 2006 (Table 3, Fig. 1).
Nalidixic acid resistance also increased and was correlated with nonsusceptibility to 
ciprofloxacin (p < 0.01). Among all isolates, 445 (1.8%) were resistant to nalidixic acid; 
93% of the nalidixic acid–resistant isolates were nonsusceptible to ciprofloxacin (Table 2).
Three Senftenberg and 1 Typhimurium isolates were resistant to both ciprofloxacin and 
ceftriaxone. In addition, 27 isolates of 10 serotypes showed both intermediate susceptibility 
to ciprofloxacin and ceftriaxone resistance. Only serotype Concord had a high proportion of 
Medalla et al. Page 4
Foodborne Pathog Dis. Author manuscript; available in PMC 2019 May 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
isolates with this pattern (three isolates; 43% of this serotype); all other serotypes had fewer 
than 5% of isolates with this pattern.
Multidrug resistance
Among the 24,903 isolates, 3,247 (13%) were MDR (resistant to ≥ 3 classes). These were of 
85 serotypes; most were Typhimurium (60%), Newport (12%), or Heidelberg (5.6%) (Table 
2). MDR was most common in serotypes Concord (71%), Choleraesuis (58%), Dublin 
(42%), Corvallis (38%), Typhimurium (37%), Derby (34%), Stanley (29%), Blockley (25%), 
and Hadar (22%). Overall, MDR decreased from 17% in 1996 to 9.6% in 2009 (OR = 0.6, 
95% CI 0.5–0.7) (Table 3, Fig. 1). Among serotype Typhimurium, MDR declined from 50% 
in 1996 to 28% in 2009 (OR = 0.4, 95% CI 0.3–0.6). Among serotype Newport isolates, 
MDR increased from 5.9% in 1996 to a peak of 31% in 2001, declining to 8.4% in 2009 
(Fig. 1). Among serotype Heidelberg isolates, MDR increased from 12% in 1996 to 17% in 
2007, jumped to 28% in 2008, and was found in 26% in 2009 (1996 vs. 2009; OR = 2.6, 
95% CI 1.1–6.2) (Table 3, Fig. 1).
The five most common MDR phenotypes were ACSSuT (41% of MDR isolates), 
ACSSuTAuCx (15%), ASSuT (9.1%), SSuT (8.5%), and AAuCx (4.3%). Many of these 
isolates were also resistant to some of the agents not included in defining resistance patterns.
The 1323 ACSSuT isolates were of 26 serotypes; 90% were Typhimurium. This serotype 
had the highest percentage of isolates with the ACSSuT pattern (23%). ACSSuT resistance 
declined from 8.2% in 1996 to 3.6% in 2009 (OR = 0.4, 95% CI 0.3–0.6). Among serotype 
Typhimurium, ACSSuT resistance declined from 32% in 1996 to 18% in 2009 (OR = 0.5, 
95% CI 0.3–0.7) (Table 3, Fig. 1).
The 476 ACSSuTAuCx isolates were of 16 serotypes; 68% were Newport. This serotype had 
the highest percentage of isolates with the ACSSuTAuCx pattern (14%). ACSSuTAuCx 
resistance increased from 0% in 1996 to 1.4% in 2009 (95% CI 5.8–infinity) (Table 3, Fig. 
1). Among serotype Newport, ACSSuTAuCx increased from 0% in 1996 to a peak of 25% in 
2001, declining to 7.1% in 2009 (Fig. 1). Most (65%) ceftriaxone-resistant isolates were 
ACSSuTAuCx. Among serotype Newport, 97% of ceftriaxone-resistant isolates were 
ACSSuTAuCx.
The 295 ASSuT isolates were of 27 serotypes; 75% were Typhimurium. The serotypes with 
the highest percentage of ASSuT-resistant isolates were Choleraesuis (25%), 
Bovismorbificans (5.4%), and Typhimurium (4.2%). The ASSuT pattern declined from 1.5% 
in 1996 to 0.5% in 2009 (OR = 0.4, 95% CI 0.2–0.8). Among serotype Typhimurium, it 
declined from 4.6% to 1.1% (OR = 0.3, 95% CI 0.1–0.9) (Table 3, Fig. 1).
The 275 SSuT isolates were of 31 serotypes; most were Typhimurium (27%), Stanley 
(13%), Derby (10%), or Heidelberg (10%). The serotypes with the highest percentage of 
SSuT-resistant isolates were Corvallis (38%), Derby (28%), and Stanley (20%). There was 
no change in SSuT resistance (Table 3, Fig. 1).
The 140 AAuCx isolates were of 18 serotypes; most were serotype Heidelberg (37%) or 
Typhimurium (36%). The serotype with the highest percentage of AAuCx resistant isolates 
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was Heidelberg (4.0%). AAuCx increased from 0.1% in 1996 to 1.0% in 2009 (OR = 18, 
95% CI 2.3–131). Among serotype Heidelberg, AAuCx was first detected in 2000 and 
increased to 8.1% in 2009 (1996 vs. 2009, 95% CI 1.7–infinity) (Table 3, Fig. 1). Of the 81 
ceftriaxone-resistant Heidelberg isolates, 52 (64%) had the AAuCx pattern, and 28 (35%) 
were resistant to A, Au, Cx, and at least one of the other four agents (C, S, Su, T).
Discussion
We describe an increase in resistance to ceftriaxone and a similar trend in resistance to 
ceftiofur, a closely related extended-spectrum cephalosporin used in some food animals in 
the United States (Alcaine et al., 2005; McDermott, 2006). Resistance to ceftriaxone and 
ceftiofur in Salmonella results from the presence of a plasmid-encoded AmpC-like β-
lactamase, CMY-2 (Giles et al., 2004; Alcaine et al., 2005; Whichard et al., 2007). A 
fivefold increase in the proportion of human Salmonella isolates resistant to extended-
spectrum cephalosporins reported from 1998 through 2001 was primarily attributed to the 
emergence of Newport strains with the ACSSuTAuCx phenotype; cattle on local dairy farms 
were identified as a reservoir (Gupta et al., 2003). A study of sporadic infections implicated 
bovine and possibly poultry sources (Varma et al., 2006). In general, sources of susceptible 
infections appear to be different from those of MDR infections (Greene et al., 2008). 
Because cattle are a major source of human serotype Newport infections resistant to 
ACSSuTAuCx, a decline in this MDR pattern in human isolates may be attributed mainly to 
a decline in ACSSuTAuCx resistance among serotype Newport in cattle (Gupta et al., 2003; 
NARMS, 2011).
The parallel increase in ceftriaxone resistance and the ACSSuTAuCx pattern observed in 
serotype Newport has not been observed in Heidelberg, another serotype in which 
ceftriaxone resistance has increased. In serotype Heidelberg, resistance is mediated by an 
IncI group of plasmids that appear less prone to acquire multiple resistance genes than the 
IncA/C plasmids mediating resistance in serotype Newport (Giles et al., 2004; Whichard et 
al., 2007; Folster et al., 2009). This helps explain our observation that serotype Heidelberg 
has the highest percentage of isolates with the AAuCx pattern. Infection with serotype 
Heidelberg has been mainly attributed to consumption of poultry and eggs (McDermott, 
2006; Dutil et al., 2010; CDC, 2011b). There is evidence that use of ceftiofur in poultry is 
contributing to third-generation cephalosporin resistance in human Heidelberg infections 
(Dutil et al., 2010).
The increase in nonsusceptibility to ciprofloxacin, which correlates with nalidixic acid 
resistance, is of concern because it has been associated with increased risk for treatment 
failure in invasive infections (CLSI, 2012; Crump et al., 2003). It is notable that 
nonsusceptibility to ciprofloxacin has increased in serotype Enteritidis, which is rarely 
resistant to other agents (CDC, 2012). Enteritidis was the most common serotype among 
isolates with this pattern. Shell eggs are a major vehicle for Enteritidis infection (Braden, 
2006). Enteritidis infections have also been linked to international travel and to consuming 
chicken (Kimura et al., 2004; Johnson et al., 2011). United Kingdom studies have associated 
quinolone-resistant infections with foreign travel and consumption of imported foods 
(Threlfall et al., 2006).
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The decline in MDR among Salmonella has been driven mainly by decreased MDR among 
serotype Typhimurium. However, MDR peaked in serotype Newport in 2001 and has 
increased in serotype Heidelberg. Of the five most common patterns, ACSSuT and ASSuT 
have declined, SSuT has not changed, but patterns containing ceftriaxone resistance (i.e., 
ACSSuTAuCx and AAuCx) have increased. The predominance of ACSSuTAuCx in 
ceftriaxone-resistant isolates, particularly in serotype Newport, illustrates the accumulation 
of linked genes on transmissible plasmids (McDermott, 2006). Because MDR plasmids may 
be maintained by selection pressure from a single agent for which there is resistance, 
populations carrying these plasmids may be difficult to eradicate. For example, multidrug-
resistant Salmonella may be selected for by use of agents that are routinely added to feed or 
water of healthy food animals, such as tetracyclines (Mellon et al., 2001). Of the five most 
common MDR patterns, four include tetracycline resistance.
To account for the change in NARMS catchment over time, possible confounding by site, 
and to assess interaction between site and year, we adjusted for site in most of the regression 
models. However, because of sparse data, we categorized site by nine regions instead of 50 
states (CDC, 2012). Thus, our analysis lacked power to determine the effect of state-to-state 
variation in resistance. In models that did not adjust for site, reported OR represents a 
summary of possibly unequal trends across sites. We also did not adjust for multiple 
comparisons. If illness caused by resistant Salmonella tends to be more severe and thus more 
likely to receive medical attention, we may have overestimated the percentage of resistant 
infections. However, this could not have changed the direction of trends in resistance over 
time.
Identification of rare but worrisome resistance patterns can help alert clinicians and target 
prevention efforts. We detected resistance to ceftriaxone and ciprofloxacin in four isolates, 
three of which were serotype Senftenberg (Whichard et al., 2007). An outbreak that involved 
several health care facilities and affected mostly elderly patients was linked to serotype 
Senftenberg with this pattern (Kay et al., 2007). Many other serotypes in which a high 
proportion of isolates had important resistance patterns cause a relatively small proportion of 
human Salmonella infections (CDC, 2012). These include serotypes Blockley, Choleraesuis, 
Concord, Corvallis, Derby, Dublin, Hadar, Stanley, and Virchow. However, identifying their 
reservoirs and determining ways to decrease selective pressure may decrease the likelihood 
of further emergence of resistant strains and spread of their plasmids.
There is evidence that antimicrobial resistance among Salmonella is predominantly a 
consequence of antimicrobial use in food animals (Angulo et al., 2004). The FDA has taken 
steps to contain the spread of antimicrobial-resistant bacteria in food animals and prolong 
the usefulness of antimicrobial agents. In 2003, the FDA incorporated a qualitative review 
process into the pre-approval safety assessment of agents for food-producing animals (FDA, 
2003). In 2005, the FDA withdrew approval of the fluoroquinolone enrofloxacin from use in 
poultry (FDA, 2005). In 2012, the FDA introduced restrictions on extra-label use of 
extended-spectrum cephalosporins in food animals (FDA, 2012a). In 2012, the FDA also 
announced plans for initiating a strategy for limiting use of important agents in food-
producing animals to those that are for therapeutic purposes and are administered under 
veterinary supervision (FDA, 2012b). These and other approaches are needed to prevent the 
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emergence and spread of resistant Salmonella in food animals and transmission to humans. 
Because of concerns that nontherapeutic use of agents selects for resistance and that 
resistance genes can disseminate via the food chain, many European Union countries have 
banned use of antimicrobial growth promoters in food animal production and coupled these 
bans to improved production practices (Cogliani et al., 2011). U.S. efforts are needed to 
reduce unnecessary use of antimicrobial agents in food animals to slow the emergence and 
spread of resistance and maintain efficacy of agents for the treatment of human infections.
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FIG. 1. 
Percentage of selected resistance patterns among all nontyphoidal Salmonella isolates and 
the four most commonly isolated serotypes, by year, 1996–2009. Minimum inhibitory 
concentration (MIC) interpretive criteria (when available) for resistance and classes of 
antimicrobial agents defined by the Clinical and Laboratory Standards Institute were used. 
Nonsusceptibility (NS) to ciprofloxacin was defined as MIC ≥ 0.12 μg/mL. Multidrug 
resistance patterns were based on resistance to 7 of 15 agents: ampicillin (A), 
chloramphenicol (C), streptomycin (S), sulfonamide (Su), tetracycline (T), amoxicillin-
clavulanic acid (Au), and ceftriaxone (Cx), e.g., ACSSuT includes resistance to A, C, S, Su, 
and T, and no resistance to Au and Cx. Resistance to the other agents may be present.
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TABLE 1.
PARTICIPATING STATES IN THE NATIONAL ANTIMICROBIAL RESISTANCE MONITORING SYSTEM, BY YEAR, 1996–2009
Year No. statesa New sites
1996 13 California (Alameda, Los Angeles, and San Francisco counties), Colorado, Connecticut, Florida, Georgia, Kansas, 
Massachusetts, Minnesota, New Jersey, New York (Bronx, Brooklyn, New York, Queens, and Richmond counties), 
Oregon, Washington, and West Virginia
1997 14 Maryland
1999 15 Tennessee
2002 26 Arizona, Hawaii, Louisiana, Maine, Michigan, Montana, Nebraska, New Mexico, South Dakota, Texas (excluding 
Houston), and Wisconsin; New York began statewide participation
2003 50 Alaska, Alabama, Arkansas, Delaware, Iowa, Idaho, Illinois, Indiana, Kentucky, Missouri, Mississippi, North Carolina, 
North Dakota, New Hampshire, Nevada, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Utah, Virginia, 
Vermont, Wyoming, remaining counties in California, and Houston
2008 50 District of Columbia
2009 50
a
Represented by state and local health departments and their public health laboratories.
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